IGMPI India

During the state visit of President of the Republic of Korea, a Memorandum of Understanding in the area of therapeutic products was signed between the Korean Ministry for Food and Drug Safety (MFDS) and Swiss Regulatory Authority Swissmedic.

Swissmedic is the Swiss authority responsible for the authorization and supervision of therapeutic products and their activities are based on the Law on Therapeutic Products. Swissmedic has extended its network on the basis of agreements with partner authorities, thus escalating international collaboration. A total of ten such agreements have been signed to date, including with the authorities in Australia, Brazil, Japan, Canada, New Zealand, Singapore and the USA and three authorities in EU countries(the Paul-Ehrlich Institute and the German Federal Institute for Drugs and Medical Devices in Germany and the Irish Medicines Board in Ireland).

With this, the authority serves to protect the health of the citizens, against a backdrop of the increasing globalization and production of therapeutic products. The agreement consists of a formal basis for further understanding of each institution's regulatory framework conditions, requirements and processes, and for launching concrete initiatives for collaboration.

This clearly shows the commitment towards intensifying international collaboration. In light of an increasing globalization and therefore in a continually changing regulatory environment and new technological and scientific developments this is an important step to take. After all this results in a win-win situation for everybody involved.